p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells
Abstract Increasing evidence suggests that an inflammatory microenvironment promotes invasion by glioblastoma (GBM) cells. Together with p38 mitogen-activated protein kinase (MAPK) activation being regarded as promoting inflammation, we hypothesized that elevated inflammatory cytokine secretion and p38 MAPK activity contribute to expansion of GBMs. Here we report that IL-1β, IL-6, and IL-8 levels and p38 MAPK activity are elevated in human glioblastoma specimens and that p38 MAPK inhibitors attenuate the secretion of pro-inflammatory cytokines by microglia and glioblastoma cells. RNAi knockdown and immunoprecipitation experiments suggest that the p38α MAPK isoform drives inflammation in GBM cells. Importantly, p38 MAPK inhibition strongly reduced invasion of U251 glioblastoma cells in an inflammatory microenvironment, providing evidence for a p38 MAPK-regulated link between inflammation and invasiveness in GBM pathophysiology..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
|---|---|
| Enthalten in: |
Journal of neuro-oncology - 109(2012), 1 vom: 19. Apr., Seite 35-44 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yeung, Yiu To [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Glioblastoma |
|---|
| Anmerkungen: |
© Springer Science+Business Media, LLC. 2012 |
|---|
| doi: |
10.1007/s11060-012-0875-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2037136269 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2037136269 | ||
| 003 | DE-627 | ||
| 005 | 20230624215939.0 | ||
| 007 | tu | ||
| 008 | 200820s2012 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11060-012-0875-7 |2 doi | |
| 035 | |a (DE-627)OLC2037136269 | ||
| 035 | |a (DE-He213)s11060-012-0875-7-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Yeung, Yiu To |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media, LLC. 2012 | ||
| 520 | |a Abstract Increasing evidence suggests that an inflammatory microenvironment promotes invasion by glioblastoma (GBM) cells. Together with p38 mitogen-activated protein kinase (MAPK) activation being regarded as promoting inflammation, we hypothesized that elevated inflammatory cytokine secretion and p38 MAPK activity contribute to expansion of GBMs. Here we report that IL-1β, IL-6, and IL-8 levels and p38 MAPK activity are elevated in human glioblastoma specimens and that p38 MAPK inhibitors attenuate the secretion of pro-inflammatory cytokines by microglia and glioblastoma cells. RNAi knockdown and immunoprecipitation experiments suggest that the p38α MAPK isoform drives inflammation in GBM cells. Importantly, p38 MAPK inhibition strongly reduced invasion of U251 glioblastoma cells in an inflammatory microenvironment, providing evidence for a p38 MAPK-regulated link between inflammation and invasiveness in GBM pathophysiology. | ||
| 650 | 4 | |a Glioblastoma | |
| 650 | 4 | |a Tumour microenvironment | |
| 650 | 4 | |a p38 MAPK inhibitors | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Invasion | |
| 700 | 1 | |a Bryce, Nicole S. |4 aut | |
| 700 | 1 | |a Adams, Seray |4 aut | |
| 700 | 1 | |a Braidy, Nady |4 aut | |
| 700 | 1 | |a Konayagi, Mari |4 aut | |
| 700 | 1 | |a McDonald, Kerrie L. |4 aut | |
| 700 | 1 | |a Teo, Charles |4 aut | |
| 700 | 1 | |a Guillemin, Gilles J. |4 aut | |
| 700 | 1 | |a Grewal, Thomas |4 aut | |
| 700 | 1 | |a Munoz, Lenka |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuro-oncology |d Springer US, 1983 |g 109(2012), 1 vom: 19. Apr., Seite 35-44 |w (DE-627)167915800 |w (DE-600)604875-4 |w (DE-576)015902951 |x 0167-594X |7 nnns |
| 773 | 1 | 8 | |g volume:109 |g year:2012 |g number:1 |g day:19 |g month:04 |g pages:35-44 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11060-012-0875-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 109 |j 2012 |e 1 |b 19 |c 04 |h 35-44 | ||